Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anti-BCMA anti-CD38 bispecific chimeric antigen receptor T cell therapy - Shengyan Pharmaceutical Technology

Drug Profile

Anti-BCMA anti-CD38 bispecific chimeric antigen receptor T cell therapy - Shengyan Pharmaceutical Technology

Alternative Names: BCMA-CD38 Bispecific CAR-Modified T Cells; BCMA-CD38 bispecific CAR-T cells; BM38 bivalent CAR-T cells

Latest Information Update: 21 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shengyan Pharmaceutical Technology
  • Developer Shengyan Pharmaceutical Technology; Wuhan Union Hospital
  • Class CAR-T cell therapies; Gene therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Multiple myeloma

Most Recent Events

  • 07 Dec 2019 Efficacy and adverse events data from a phase-I trial in Multiple myeloma presented at the 61st Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem-2019)
  • 15 Jun 2019 Efficacy and safety data from a phase I trial in Multiple myeloma presented at the 24th Congress of the European Haematology Association (EHA-2019)
  • 01 Sep 2018 Phase-I clinical trials in Multiple myeloma (Second-line therapy or greater) in China (Parenteral) (ChiCTR1800018143)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top